Category: ASH

ONCrg Live: ASH 2026 Preview

Between pre-conference prep and thousands of abstracts, navigating ASH is tough. Oncology Resource Group is hosting a quick overview to break down what actually matters ahead of New Orleans. If you’re in biopharma commercial, CI, or medical affairs, join us for ONCrg Live: ASH 2026 Preview on Thursday, Dec 10 at 11:00 AM ET. We’ll […]

Headed to ASH 2026 in New Orleans? So are we!

The ONCrg (Oncology Resource Group) team will be on-site tracking key data readouts, clinical paradigm shifts, and strategic pipeline updates across hematology.   Here’s what our analyst team is monitoring based on our conference coverage: 📌 𝐇𝐢𝐠𝐡 𝐈𝐦𝐩𝐚𝐜𝐭 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐅𝐨𝐜𝐮𝐬 𝐀𝐫𝐞𝐚𝐬: • AML/MDS (Targeted agents, including menin-KMT2A/MLL inhibitors) • NHL/CLL (BTK inhibitors and B-cell targeted […]

Pre-ASH 2025 Analyst Briefing: Webinar

Executive Summary: ONCrg analyst Patrick Nygren previews the highest-impact clinical presentations across hematologic malignancies at ASH 2025, covering CLL, multiple myeloma, NHL, and AML, with a focus on practice-changing phase 3 readouts and early-stage combination signals.

Antibody Drug Conjugates

Medical Conference Coverage SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026  ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 EHA: June 10-13, 2027 ICML: June 15-19, 2027 WCLC: September 11-14, 2027 ESMO: September 17-21, 2027 Antibody-Drug Conjugates (ADCs) […]

Non-Hodgkin’s Lymphoma

Excerpt from Custom Post Type Indication: NHL

Myeloproliferative Neoplasms

Excerpt from Custom Post Type Indication: MPNs

Multiple Myeloma

Excerpt from Custom Post Type Indication: MM

Myelodysplastic Syndromes

Excerpt from Custom Post Type Indication: MDS

Chronic Lymphocytic Leukemia

Excerpt from Custom Post Type Indication: CLL

Acute Myeloid Leukemia

Excerpt from Custom Post Type Indication: AML

    Sample Request

    How Did You Hear About Us